| Chemotherapy Regimen |
Survival, Median (months) |
Hazard Ratio |
Objective Response Rate |
Toxicities (grade ¾) |
Author References |
| Gemcitabine (versus 5-FU) |
5.65 (vs. 4.41) |
not reported |
5.4 |
Neutropenia 25.9% |
[93,100] |
| Gemcitabine + erlotinib (verus gemcitabine) |
6.24 (vs. 5.9) |
0.82 |
no significant difference (values not provided) |
62% (Fatigue 15%, Infection 17%) |
[97] |
| FOLFIRINOX (versus gemcitabine) |
11.1 (vs. 6.8) |
0.57 |
31.6 |
Fatigue 23.6% Neutropenia 45.7% |
[98] |
| gemcitabine + nab-paclitaxel (versus gemctabine) |
8.5 (vs 6.7) |
0.72 |
23 |
Fatigue 17% Neutropenia 38% |
[99] |